Key Takeaways From FDA Warnings To CBD Cos.

Law360

Partner Donnelly McDowell co-authored the Law360 article, Key Takeaways From FDA Warnings To CBD Cos.”. The article highlights important takeaways from and discusses the implications of two recent warning letters the FDA issues to makers of topical CBD products labeled as over-the-counter, or OTC, drugs.

To read the full article, click here. Access may require a subscription.